A team of researchers at Mass General Cancer Center has reviewed the state of research surrounding FLT3 inhibitors.
Departments, Centers, & Programs:
Mass General Hospital Cancer Center
55 Fruit Street
Boston, MA 02114-2696
1575 Cambridge Street
Cambridge, MA 02138-4308
- MD, University of Miami
- M.D.; Ph.D., University of Miami School of Medicine
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
- Fellowship, Dana-Farber Cancer Institute
American Board Certifications
- Medical Oncology, American Board of Medical Oncology
- Medical Oncology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Wander SA, Mayer EL, Burstein HJ. Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 Sep 1;35(25):2866-2870. Cited in PubMed; PMID: 28580881.
Zhao D, Besser AH, Wander SA, Sun J, Durante MA, Wang B, Ince T, Zhou W, Guo W, Mills G, Theodorescu D, Slingerland JM. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated twist1 upregulation. Oncogene. 2015 Oct;34(43):5447-59. Cited in PubMed; PMID: 25684140.
Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment. 2013 Apr; 138(2): 369-81. Cited in PubMed; PMID: 23430223.
Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. The Journal of Clinical Investigation (JCI). 2011 Apr; 121(4): 1231-41. Cited in PubMed; PMID: 21490404.
Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clinical Cancer Research. 2011 Jan; 17(1): 12-18. Cited in PubMed; PMID: 20966355.